Indaptus Therapeutics
INDP
9 hedge funds and large institutions have $1.15M invested in Indaptus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
798% more capital invested
Capital invested by funds: $129K → $1.15M (+$1.03M)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more funds holding
Funds holding: 6 → 9 (+3)
2.81% less ownership
Funds ownership: 3.15% → 0.34% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$519K |
| 2 |
Jane Street
New York
|
+$135K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$84.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$74.2K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$35.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$71K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $618K | +$519K | +206,077 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $169K | +$74.2K | +29,463 | +109% |
|
|
3
Jane Street
New York
| $161K | +$135K | +53,811 | New |
|
|
4
Vanguard Capital Management
Malvern,
Pennsylvania
| $101K | +$84.7K | +33,652 | New |
|
|
5
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $41.9K | +$35.2K | +13,967 | New |
|
6
Millennium Management
New York
| $34.8K | +$29.2K | +11,586 | New |
|
7
Morgan Stanley
New York
| $26.8K | +$15.7K | +6,239 | +231% |
|
8
UBS Group
Zurich,
Switzerland
| $1.43K | +$1.2K | +478 | New |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $51 | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$71K | -39,018 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$3.44K | -1,890 | Closed |
|
INDP Hedge Fund Activity: Q2 2026 in Review
9 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2026, worth a combined $1.15M — up 798% from $129K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INDP positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $519K. The largest seller was Citadel Advisors, exiting entirely with an estimated $71K sold.
- 9 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2026, up from 6 in Q1 2026.
- Funds reported $1.15M of Indaptus Therapeutics stock for Q2 2026, up 798% quarter-over-quarter.
- 6 funds opened new Indaptus Therapeutics positions in Q2 2026 and 2 closed out, a net change of +4 holders.
- The largest Indaptus Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $519K added.
- The largest Indaptus Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $71K sold.
Based on aggregated 13F filings for Q2 2026.